José Pedro Friedmann Angeli

This study identifies artesunate as a drug that targets redox vulnerabilities in metastatic lung adenocarcinoma by exploiting glutathione-dependent mechanisms.

This study identifies LXR as an oxysterol-sensing suppressor of ferroptosis by promoting lipid remodeling that reduces lipid peroxidation.

This study identifies a heme-HMOX1-ferritin axis that protects cells from ferroptosis by stabilizing heme and upregulating ferritin when HMOX1 is inactive.

This study shows that the RNF4 ligand CCW16 induces ferroptosis in AML cells through a RNF4-independent mechanism by causing covalent protein modifications and upregulating ferroptosis markers.

This study identifies riboflavin as a modulator of ferroptosis sensitivity by supporting FSP1 stability and antioxidant recycling, with implications for therapeutic targeting.

The paper identifies PRDX6 as an alternative pathway for selenocysteine metabolism that contributes to ferroptosis resistance in cancer cells.